Back to discover
Drug

Prasugrel Hydrochloride

In clinical development
ClassPurinergic receptor P2Y12 antagonistEmerging researchLate-stage development

Also known as Effient, prasugrel (as hydrochloride), prasugrel HCl.

RxNorm847020ChEMBLCHEMBL1201773UNIIG89JQ59I13
3
Research papers
P2Y purinoceptor 12
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Prasugrel Hydrochloride
Aliases & brands
Effientprasugrel (as hydrochloride)prasugrel HCl
RxNorm CUI
847020
ChEMBL ID
CHEMBL1201773
UNII
G89JQ59I13
Primary mechanism
Purinergic receptor P2Y12 antagonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

P2Y purinoceptor 12
P2RY12 · Q9H244
ANTAGONISTPurinergic receptor P2Y12 antagonist

Clinical trials

1 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
1
registered trials across all phases
1
Late-stage (III+)
1
Discontinued
PHASE DISTRIBUTIONn = 1
Phase 31

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Prasugrel in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients

Unknown statusPH IIIAzienda Ospedaliera Universitaria Integrata Veronan=1282021

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes3
Percutaneous Coronary Intervention2Drug-Eluting Stents1Genotype1
Journals, researchers & institutions
Top journals
  • The New England journal of medicine2
  • JAMA1
Leading researchers
  • Abe M1
  • Akin I1
  • Allali A1
  • Ando K1
  • Angiolillo DJ1
  • Antoniucci D1
  • Asselbergs FW1
  • Barbato E1
Leading institutions
free-text, unnormalised
  • and Technische Universität München (S.S.1
  • Chikamori Hospital1
  • Department of Clinical Epidemiology1
  • Ehime Prefectural Central Hospital1
  • Gifu Prefectural General Medical Center1
  • Hanaoka Seishu Memorial Cardiovascular Clinic1

Related diseases

2 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas
Hemorrhage3Coronary Thrombosis2

Related drugs

3 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Ticagrelor

Acts on the same molecular target as Prasugrel Hydrochloride, with 6 overlapping disease areas.

Shared target6 shared diseases2 shared papers
Aspirin

Studied across 5 of the same disease areas as Prasugrel Hydrochloride in the shared literature.

5 shared diseases1 shared paper
Clopidogrel

Studied across 3 of the same disease areas as Prasugrel Hydrochloride in the shared literature.

3 shared diseases2 shared papers
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials